Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises NOTE in connection with the company’s underwritten rights issue
Mandate

Vinge advises NOTE in connection with the company’s underwritten rights issue

March 11, 2010

Vinge is advising NOTE AB (publ) in connection with the new issue of shares for approximately SEK 87 million with pre-emption rights for NOTE’s shareholders. The rights issue is conditional upon approval by the members at an extraordinary general meeting to be held on 7 April 2010. The new issue is fully underwritten by a subscription agreement and guarantee commitment by NOTE’s major shareholders.

NOTE is listed on NASDAQ OMX Stockholm. Note’s business concept is to provide electronics manufacturing and logistics services.

Vinge’s team consisted of Ola Sandersson, Dain Nevonen and Christian Granqvist. Bo Adrianzon is the responsible partner.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026